Every year, the American Society of Clinical Oncology (ASCO) Annual Meeting brings together cancer researchers, oncologists, and advocates to discuss the latest cancer research. Some studies presented at ASCO may eventually change how ovarian cancer is treated. Others help answer important questions patients have been asking for years.
This year, several ovarian cancer studies are drawing attention because they focus on issues patients care deeply about, including treatment options for platinum-resistant disease, how long maintenance therapy should continue, and whether newer targeted treatments can improve outcomes.
Here are five ovarian cancer studies patients and advocates should be paying attention to at ASCO 2026.
1. ROSELLA: A newer option for platinum-resistant ovarian cancer
New data from the phase III ROSELLA trial presented at ASCO 2026 reinforce earlier findings that adding relacorilant to nab-paclitaxel helps patients live longer and delays cancer progression compared with chemotherapy alone. These results are especially meaningful because the combination received FDA approval in March 2026, giving patients a new treatment option backed by strong clinical evidence. For many patients, this marks an important step forward in improving outcomes in a setting where advances have historically been difficult to achieve.
More details on the study here.
2. Early findings suggest that fasting around chemo sessions may boost ovarian cancer outcomes
A small phase II study in patients with advanced ovarian cancer suggests that short-term fasting around chemotherapy may improve treatment outcomes. Patients who fasted for 36 hours before and 24 hours after treatment had stronger tumor responses and remained free from cancer progression longer than those who ate normally. While the approach appeared safe and feasible, larger studies are needed to confirm these results. Be sure to talk to your doctor before fasting during chemotherapy.
More details on the study here.
3. CHIPRO trial highlights new treatment combo for platinum-resistant or refractory ovarian cancer
The CHIPRO trial found that adding chiauranib, a targeted oral drug, to weekly paclitaxel (chemotherapy) significantly improved outcomes for patients with platinum-resistant or refractory ovarian cancer. The combination reduced the risk of cancer getting worse or death by 57% and more than doubled the tumor response rate compared with paclitaxel alone. These results are especially encouraging because treatment options are limited in this setting, suggesting this combination could become a promising new treatment option.
More details on the study here.
4. Chemotherapy-free option under study for patients with limited treatment choices
An early-phase study looked at a new, chemotherapy-free combination of two immunotherapy drugs for people with platinum-resistant ovarian cancer, a form of cancer that is often hard to treat. The results showed that some patients lived longer than expected, with the best outcomes seen in those receiving the higher dose of treatment. Side effects were fairly common and included immune-related issues, but most were manageable with medical care and monitoring. Overall, these findings suggest this combination could become a new treatment option for patients who have limited choices, but more research is needed to confirm the benefits.
More details on the study here.
5. Could a one-time immune therapy change treatment for advanced ovarian cancer?
A new treatment called IMA203CD8 is being studied in advanced ovarian cancer for patients who have already been through several rounds of treatment. In early results, many patients in the study saw their tumors shrink or their cancer stop growing, and some of these benefits lasted for many months to over a year. While research is still ongoing, these findings suggest this one-time immune therapy infusion could become an important new option for patients in the future.
More details on the study here.
Why this matters for patients
Large cancer meetings like ASCO can feel overwhelming, especially when headlines start appearing without a clear explanation of what the research could mean for patients today. Not every study will change treatment immediately, and early excitement does not always translate into long-term benefit. These meetings can provide an important glimpse into where ovarian cancer care is heading.
For patients, staying informed can help support better conversations with your care team. You don’t need to understand every abstract. But knowing which studies may matter can help you ask stronger questions about your treatment options, side effects, recurrence risk, and clinical trials.
Outcomes4Me is here to help you better understand your diagnosis and treatment options. You deserve clear, trustworthy information at every step.
